Efficacy and safety of omalizumab therapy in urticaria vasculitis.

Petrelli, Fiorella; Giannini, Daiana; Bilia, Silvia; Corso, Isabella Del; Rocchi, Valeria; Migliorini, Paola; Puxeddu, Ilaria

Petrelli, Fiorella; Giannini, Daiana; Bilia, Silvia; Corso, Isabella Del; Rocchi, Valeria; Migliorini, Paola; Puxeddu, Ilaria.

Afiliação

Petrelli F; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Giannini D; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Bilia S; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Corso ID; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Rocchi V; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Migliorini P; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Puxeddu I; Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.

Front Allergy ; 3: 952079, 2022.

Article em En | MEDLINE | ID: mdl-35935020

Palavras-chave

anti IgE; biological agent; omalizumab; therapy; urticarial vasculitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Allergy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google